Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Link Technologies Announces Expansion into the Far East with New Distributor

Published: Thursday, June 13, 2013
Last Updated: Thursday, June 13, 2013
Bookmark and Share
Zirench Technology signed as local distributor for the Chinese market.

Link Technologies Ltd has announced Zirench Technology Co. Ltd as distributor in China, the first Asian distributor for its comprehensive range of products.

Located in Dalian City, Zirench Technology will represent Link Technologies in China, expanding their reach across the country and providing invaluable local support for customers.

The appointment of Zirench Technology is the first signing of multiple, upcoming distributorship agreements in the Far East, and is testament to Link Technologies’ on-going strategic development and growth.

As an ISO 9001:2008 certified supplier of products for oligonucleotide synthesis, Link Technologies is committed to providing all customers with high purity, reliable oligo precursors and reagents, which can now extend to customers in China, thanks to Zirench Technology.

Commenting on the new distributor agreement, Dr John Bremner, CEO at Link Technologies, said: “We are working hard to effectively deliver our products to customers in research and industrial institutions in Asia and other parts of the world, where easily accessible local support and expertise is very important. We are delighted that this deal with Zirench boosts this strategy.”

Dr Victor Liu, Commercial Manager at Zirench Technology, added “Our aim is to offer our customers laboratory instruments, supplies and biological agents of world-class quality. As such, we were keen to act on behalf of Link Technologies, to raise awareness of and distribute their high quality oligo precursor products across China.”

Providing a broad catalogue of reagents for DNA, RNA and PNA synthesis, Link Technologies has particular expertise in the manufacture of modified nucleic acid products, often unavailable elsewhere.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

LINK Strengthens Board with Appointment of Marc Lemaître
Lemaître to join Link Technologies Ltd. as non-executive Director.
Wednesday, February 25, 2015
New SAB Supports LINK’s Growing Range of Innovative Reagents
LINK creates SAB with Brian Sproat and Thomas Rupp as first two appointments.
Friday, January 16, 2015
LINK Appoints New CEO
LINK has appointed Dr David Ricketts as its new Chief Executive Officer.
Tuesday, September 30, 2014
PNA Monomers: A Licence to Deal
Link Technologies to manufacture and sell PNA Monomers following deal with PNA Inventor Group.
Friday, June 22, 2007
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!